10,017 Shares in Bristol Myers Squibb Company $BMY Purchased by K.J. Harrison & Partners Inc

K.J. Harrison & Partners Inc acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,017 shares of the biopharmaceutical company’s stock, valued at approximately $540,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of BMY. Brighton Jones LLC raised its stake in Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Sivia Capital Partners LLC raised its stake in Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 2,786 shares during the period. United Bank raised its stake in Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,277 shares during the period. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb during the second quarter worth about $221,000. Finally, Nebula Research & Development LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth about $405,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks (covered on Yahoo Finance) highlights BMY as a top value stock for long?term investors, emphasizing attractive style scores and dividend appeal that support buy?and?hold interest. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
• Positive Sentiment: BMY is named in reports about BioNTech expanding pivotal oncology trials done in collaboration with Bristol Myers Squibb—this pipeline activity can boost long?term revenue potential if trials progress. BioNTech Expands Oncology Trials And Reshapes Manufacturing As Investors Weigh Upside
• Positive Sentiment: BMY will participate at the Bank of America Securities Healthcare Conference, giving management a forum to reinforce guidance, pipeline timelines and commercialization plans—an opportunity to reassure investors. Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
• Neutral Sentiment: BMY launched a nationwide “Won’t Lose” World Cup?focused patient campaign to raise brand awareness; marketing may aid long?term patient engagement but has limited immediate earnings impact. Bristol Myers Squibb World Cup Push Meets Valuation And Earnings Questions
• Neutral Sentiment: Analysts’ Q1 call questions (MSN recap) show market attention on growth drivers and margin dynamics—such scrutiny can amplify short?term volatility even when fundamentals are intact. Bristol-Myers Squibb’s Q1 earnings call: Our top 5 analyst questions
• Neutral Sentiment: Commentary questioning whether BMY still offers value after a ~25% one?year share gain highlights investor debate over valuation vs. yield; this may encourage profit taking. Is Bristol Myers Squibb (BMY) Offering Value After A 25.7% One Year Share Price Gain

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $56.18 on Friday. The firm’s 50 day moving average is $59.28 and its two-hundred day moving average is $54.91. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The firm has a market capitalization of $114.73 billion, a P/E ratio of 15.78, a PEG ratio of 0.16 and a beta of 0.26. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.29 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 70.79%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BMY shares. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Cantor Fitzgerald raised their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, April 8th. Bank of America dropped their price target on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Finally, Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.